The initial discovery of embelin as an inhibitor of XIAP by virtue of its interaction with the BIR3 domain and its observed selectivity towards cancer cells as compared to the normal cells inspired us to consider it as a lead compound for further studies against cancer [6]. Here, XIAP is linked to cancer.